HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Regulatory moratorium

This article was originally published in The Rose Sheet

Executive Summary

Regulatory moratorium: Bipartisan substitute to regulatory moratorium bill (S 219), co-sponsored by Sens. Don Nickles (R-OK) and Harry Reid (D-NV), is set for floor debate March 27. Nickles will offer the substitute as an amendment replacing Sen. William Roth's (R-DE) "Regulatory Transition Act," S 219. The amendment establishes a "fast-track" procedure under which Congress would have 45-days to review any final rule and enact a joint resolution of disapproval on a reg. The joint resolution of disapproval may be vetoed by the President, but Congress may override the veto. The measure provides that any senator or representative may introduce a resolution of disapproval, to be referred to the committees of jurisdiction. A similar measure is included in regulatory reform legislation adopted March 23 by the Senate Governmental Affairs Committee...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001458

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel